Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Xience V / Promus Drug-Eluting Stent Is Off And Running On U.S. Market

This article was originally published in The Gray Sheet

Executive Summary

Abbott remains confident that it will gain 25% to 30% share of the U.S. drug-eluting stent market over the next year now that it has launched its Xience V everolimus-eluting stent
Advertisement

Related Content

Xience Prime time
J&J Nevo Stent Inhibits Tissue Proliferation Better Than Boston Sci’s Liberté
Abbott’s Xience V Drives Fourth-Quarter Vascular Sales Up 60%
Abbott’s Xience Stent Launch Drives Sales, Stock Gains In Third Quarter
Medtronic Spinal Division Shows Signs Of Turnaround Under New Chief
Abbott Reports Xience Stent Launch Off To A Good Start
Taxus Free: Angiotech Carves Out New $625 Million Subsidiary
Endeavor Stent’s Debut Drives 22% Growth In Medtronic Cardiovascular Biz
Endeavor Stent’s Debut Drives 22% Growth In Medtronic Cardiovascular Biz
Abbott’s Xience Stent Drives 35% Growth In Overseas Vascular Sales
Advertisement
UsernamePublicRestriction

Register

MT026311

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel